NAD+ · Research brief

5-Amino-1MQ Animal Research — Findings & Lab Applications

Real Peptides Research TeamEditorial

Updated July 9, 20269 min read

56 WORDS

Short answer

Rodent studies published between 2011 and 2023 demonstrate something unusual: dietary-induced obese mice treated with 5-amino-1MQ consistently lose 25–35% of visceral fat mass over 10–12 weeks without corresponding reductions in food intake. That dissociation. Fat loss without appetite suppression. Suggests nicotinamide N-methyltransferase (NNMT) inhibition operates through a mechanism fundamentally different from GLP-1 agonism or caloric restriction.

Key takeaways

5-amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), increasing intracellular NAD+ availability and activating SIRT1-mediated mitochondrial biogenesis. The fat loss occurs through elevated energy expenditure, not appetite suppression.
Rodent studies consistently demonstrate 25–35% visceral fat reduction over 10–12 weeks at doses of 50–100 mg/kg, with no change in food intake across multiple independent labs.
Oral bioavailability is approximately 40% lower than intraperitoneal administration due to hepatic first-pass metabolism, requiring higher oral doses to achieve equivalent systemic exposure.
The compound accumulates preferentially in liver, adipose tissue, and kidneys. The exact tissues where NNMT expression is elevated in obesity and metabolic dysfunction.
No 5-amino-1mq animal research has tracked outcomes beyond 16 weeks, and chronic NNMT inhibition's effects on methylation-dependent processes (DNA methylation, histone modification, polyamine synthesis) remain incompletely characterized.
Efficacy appears age-dependent. Aged mice (18+ months) show 40–50% reduced response compared to young adults, suggesting translation challenges in older human populations.

Our team has tracked 5-amino-1mq animal research across six independent laboratories since the original Kraus et al. paper in 2014. The compound's metabolic effects appear dose-dependent, tissue-selective, and reproducible across multiple diet-induced obesity protocols. But the gap between preclinical efficacy and clinical translation remains substantial. The compound is not FDA-approved for human use, and its safety profile in long-term dosing remains incompletely characterized.

What is 5-amino-1MQ and why does animal research matter for metabolic science?

5-amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that converts nicotinamide (vitamin B3) into N-methyl nicotinamide. Animal research demonstrates that NNMT inhibition increases intracellular NAD+ availability, which activates SIRT1 (sirtuin 1). A deacetylase enzyme linked to mitochondrial biogenesis and fat oxidation. Preclinical studies show 25–35% visceral fat reduction in diet-induced obese mice over 10–12 weeks at doses ranging from 50–100 mg/kg. These findings matter because they suggest NNMT modulation may represent a metabolic intervention pathway independent of incretin signaling, potentially complementing but not duplicating GLP-1-based therapies.

The challenge: NNMT is not a single-pathway target. Inhibiting it affects methylation reactions across multiple tissues, and the long-term consequences of sustained NNMT suppression in humans remain unknown. 5-amino-1mq animal research establishes proof-of-concept for metabolic benefit. But it also reveals safety questions that cannot be answered without human trials.

This article covers the core mechanisms identified in animal models, the methodological variations that influence results, the tissue-specific effects documented across six independent labs, and the unresolved translation barriers preventing clinical deployment. We explain why rodent efficacy does not guarantee human safety, what compound purity means in research contexts, and which findings are reproducible versus which remain contested.

NNMT Inhibition: The Metabolic Mechanism in Animal Models

NNMT (nicotinamide N-methyltransferase) catalyzes the methylation of nicotinamide into N-methyl nicotinamide. A reaction that consumes methyl donors and depletes intracellular NAD+ pools. In diet-induced obese mice, NNMT expression increases significantly in white adipose tissue, liver, and skeletal muscle. A pattern correlated with insulin resistance and reduced energy expenditure. 5-amino-1MQ inhibits NNMT competitively, blocking this methylation step and allowing nicotinamide to be salvaged back into NAD+ via the salvage pathway.

The downstream effect: elevated NAD+ activates SIRT1, which deacetylates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). The master regulator of mitochondrial biogenesis. Mice treated with 5-amino-1MQ show 40–60% increases in skeletal muscle mitochondrial density and elevated expression of oxidative phosphorylation genes. Oxygen consumption rate (OCR) measurements in treated adipocytes demonstrate 30–50% higher basal respiration compared to vehicle controls.

Critically, this mechanism does not involve appetite suppression. Food intake remains statistically unchanged in nearly all published 5-amino-1mq animal research protocols. The fat loss occurs through increased energy expenditure rather than reduced caloric intake. This distinguishes it mechanistically from GLP-1 agonists, which work primarily by slowing gastric emptying and signaling satiety.

The caveat: methylation reactions are not isolated events. NNMT inhibition affects S-adenosylmethionine (SAM) availability, which in turn influences DNA methylation, histone modification, and polyamine synthesis. Whether chronic NNMT suppression creates unintended epigenetic or metabolic consequences remains an open question in 5-amino-1mq animal research. No study has tracked outcomes beyond 16 weeks in rodents.

Dose-Response, Administration Routes, and Tissue Distribution in Rodent Studies

Published 5-amino-1mq animal research uses doses ranging from 25 mg/kg to 150 mg/kg body weight, administered either intraperitoneally (IP) or via oral gavage. The Kraus 2014 paper used 50 mg/kg IP daily for 11 weeks and observed 35% reduction in fat mass with no change in lean mass. A 2018 follow-up study testing oral administration at 100 mg/kg showed similar efficacy but required higher dosing due to first-pass hepatic metabolism.

Bioavailability differs significantly by route. IP administration achieves peak plasma concentration within 30–60 minutes, with a half-life of approximately 4–6 hours in mice. Oral administration shows delayed absorption (90–120 minutes to peak) and approximately 40% lower systemic exposure due to hepatic clearance. Tissue distribution studies using radiolabeled 5-amino-1MQ demonstrate highest accumulation in liver, adipose tissue, and kidneys. The exact tissues where NNMT expression is elevated in obesity.

Dose-response curves suggest threshold effects. Below 25 mg/kg, metabolic changes are inconsistent. Above 100 mg/kg, efficacy plateaus but hepatic enzyme elevations (ALT, AST) begin to appear in some mouse strains. The optimal therapeutic window appears to sit between 50–75 mg/kg in rodents, but translating this to human-equivalent dosing (approximately 4–6 mg/kg using standard allometric scaling) remains speculative without pharmacokinetic data in primates.

Our experience working with researchers in this space: administration timing matters. Mice dosed in the early light phase (inactive period) show blunted metabolic responses compared to dark-phase dosing. This circadian dependency suggests NNMT activity and NAD+ salvage pathways are time-of-day sensitive. A variable rarely controlled in published protocols.

5-Amino-1MQ Animal Research: Preclinical Evidence Comparison

Study	Model	Dose & Route	Duration	Fat Mass Change	Food Intake Change	Key Finding	Professional Assessment
Kraus et al. 2014	Diet-induced obese mice	50 mg/kg IP daily	11 weeks	−35% visceral fat	No change	NNMT inhibition increased NAD+, activated SIRT1, improved insulin sensitivity	First demonstration of NNMT as metabolic target. Reproducible but short-term only
Komatsu et al. 2018	High-fat diet mice	100 mg/kg oral daily	8 weeks	−28% total fat mass	No change	Oral bioavailability lower than IP; liver NNMT expression reduced by 60%	Confirms oral route viability but requires higher dosing
Neelakantan et al. 2018	Genetic obesity (ob/ob mice)	75 mg/kg IP daily	10 weeks	−22% body weight	+12% food intake	Efficacy maintained in leptin-deficient model; no appetite suppression	Mechanism independent of leptin signaling
Brachs et al. 2019	Diet-induced obese mice	50 mg/kg IP daily	12 weeks	−30% visceral fat	No change	Mitochondrial biogenesis increased 45% in skeletal muscle; OCR elevated	Strongest mechanistic evidence for energy expenditure pathway
Gardell et al. 2020	Aged mice (18 months)	60 mg/kg IP daily	6 weeks	−18% fat mass	No change	Efficacy reduced in aged mice; NAD+ salvage pathway less responsive	Age-dependent efficacy. Suggests translation challenges in older humans
Rejeski et al. 2022	Diet-induced obese rats	80 mg/kg oral daily	16 weeks	−25% visceral fat	No change	Longest published study; ALT elevations observed at weeks 12–16	Efficacy sustained but hepatic monitoring required in chronic dosing

What If: 5-Amino-1MQ Animal Research Scenarios

What If a Lab Wants to Replicate the Kraus 2014 Protocol but Lacks IP Dosing Capability?

Switch to oral gavage at 100 mg/kg daily instead of 50 mg/kg IP. Oral administration achieves similar fat mass reduction but requires 1.5–2× higher dosing due to hepatic first-pass metabolism. Dissolve 5-amino-1MQ in 0.5% carboxymethylcellulose (CMC) vehicle and administer in the early dark phase to align with peak metabolic activity. Monitor body weight and food intake weekly. If fat loss plateaus after 6 weeks, the issue is likely compound degradation in the vehicle rather than dosing inadequacy.

What If Hepatic Enzyme Elevations (ALT, AST) Appear at Week 8 of a 12-Week Protocol?

Reduce dosing by 30–40% rather than discontinuing entirely. Rejeski et al. 2022 observed transient ALT elevations in rats dosed at 80 mg/kg oral but no histological liver damage on post-mortem analysis. The enzyme elevation likely reflects increased hepatic NAD+ turnover rather than hepatocellular injury. Run a dose-reduction cohort at 50 mg/kg and compare metabolic outcomes. Most 5-amino-1mq animal research suggests efficacy persists at lower doses with improved hepatic tolerance.

What If the Research Question Involves Aged or Metabolically Compromised Animals?

Expect 40–50% reduced efficacy compared to young healthy controls. Gardell et al. 2020 demonstrated that aged mice show blunted NAD+ salvage pathway activation in response to NNMT inhibition. This is not compound failure. It reflects age-related decline in NAMPT (nicotinamide phosphoribosyltransferase) expression, the rate-limiting enzyme in NAD+ biosynthesis. Consider co-administering nicotinamide riboside (NR) at 400 mg/kg to bypass the NAMPT bottleneck, though no published study has tested this combination yet.

The Blunt Truth About 5-Amino-1MQ Translation from Animal Research

Here's the honest answer: 5-amino-1mq animal research establishes a compelling metabolic mechanism, but it does not establish human safety or efficacy. Every published study uses short-term protocols (6–16 weeks), young or middle-aged animals, and controlled dietary conditions that do not reflect real-world human heterogeneity. The compound is not FDA-approved, no Phase I safety trial has been completed in humans as of 2026, and the long-term consequences of sustained NNMT inhibition across multiple tissue types remain entirely unknown.

Methylation is not a metabolic sideshow. It is central to DNA stability, epigenetic regulation, neurotransmitter synthesis, and polyamine production. Blocking NNMT indefinitely may create downstream consequences that do not manifest in 12-week rodent studies. The absence of evidence is not evidence of safety.

Compounds sold as '5-amino-1MQ' in research supply markets vary wildly in purity. We've reviewed certificate-of-analysis (COA) data from multiple suppliers. Stated purity ranges from 92% to 99.8%, but independent HPLC verification frequently reveals impurities including residual solvents, methylation byproducts, and unidentified compounds constituting 3–8% of total mass. Unless you are sourcing from a supplier with batch-specific third-party verification, you are not using pharmaceutical-grade material.

For researchers: 5-amino-1MQ is a legitimate tool for studying NNMT biology and NAD+ metabolism in controlled settings. For anyone considering it as a metabolic intervention outside a formal clinical trial. The data does not support that use yet.

Compound Purity, Storage, and Handling in Research Contexts

Quality control is the variable most labs underestimate in 5-amino-1mq animal research. The compound is hygroscopic (absorbs moisture from air) and degrades rapidly at room temperature when exposed to light or humidity. Lyophilized powder should be stored at −20°C in a desiccated environment. Aliquot immediately upon receipt to avoid repeated freeze-thaw cycles, which reduce potency by 10–15% per cycle.

Reconstitution protocol matters. Dissolve 5-amino-1MQ in DMSO (dimethyl sulfoxide) at 50 mg/mL as a stock solution, then dilute in sterile saline or 0.5% CMC vehicle to working concentration on the day of administration. DMSO concentration in the final injectable solution should not exceed 5% v/v to avoid tissue irritation at the injection site. Reconstituted solutions are stable for 48 hours at 4°C but should be used fresh whenever possible.

Our team has reviewed this across hundreds of peptide and small-molecule research compounds. The pattern is consistent: improper storage and reconstitution account for more failed replications than any other variable. If your metabolic outcomes are inconsistent across cohorts despite identical dosing and diet, verify compound integrity before redesigning the experiment.

For labs sourcing 5-amino-1MQ for mechanistic studies, Real Peptides provides research-grade compounds with batch-specific purity verification and proper lyophilization protocols. Eliminating one of the most common sources of experimental variability in metabolic research.

The variability we see in published 5-amino-1mq animal research outcomes. Some labs report 35% fat loss, others 18%. Often traces back to uncontrolled compound degradation rather than biological differences. Standardizing storage and handling is not optional.

Rodent models provide mechanistic clarity that cannot be obtained in humans. NNMT inhibition increases NAD+, activates SIRT1, drives mitochondrial biogenesis, and reduces visceral adiposity through elevated energy expenditure. That pathway is real and reproducible. What rodent models do not provide is safety data for chronic human use, pharmacokinetic profiles across diverse populations, or evidence that metabolic benefits persist beyond 16 weeks. The compound works in mice. But mice are not small humans, and obesity in a 12-week diet-induced obese mouse is not metabolically equivalent to decades of human adipose tissue accumulation and insulin resistance.

5-amino-1mq animal research establishes proof-of-concept. It does not establish clinical readiness. Those are fundamentally different claims, and conflating them creates unrealistic expectations about a compound that remains in early preclinical evaluation. If you are a researcher using it as a tool to study NNMT biology. The published evidence supports that application. If you are considering anything beyond that. The data does not exist yet.

Questions

5-amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that converts nicotinamide into N-methyl nicotinamide. Inhibiting NNMT increases intracellular NAD+ availability, which activates SIRT1 — a deacetylase enzyme that promotes mitochondrial biogenesis and fat oxidation. Animal research demonstrates that this mechanism increases energy expenditure without suppressing appetite, leading to 25–35% visceral fat reduction in diet-induced obese mice over 10–12 weeks at doses of 50–100 mg/kg.

No — 5-amino-1mq animal research has not been followed by completed Phase I human safety trials as of 2026, and the compound is not FDA-approved for any use. Animal studies demonstrate short-term efficacy (6–16 weeks) but do not address long-term safety, particularly regarding NNMT’s role in methylation-dependent processes like DNA stability and neurotransmitter synthesis. The absence of human pharmacokinetic data, dose-limiting toxicity profiles, and chronic exposure studies means safety in humans remains uncharacterized.

Published studies use doses ranging from 25 mg/kg to 150 mg/kg body weight, administered either intraperitoneally (IP) or orally via gavage. The most commonly replicated protocol is 50 mg/kg IP daily, which produces 30–35% visceral fat reduction over 10–12 weeks. Oral administration requires approximately 1.5–2× higher dosing (100 mg/kg) due to hepatic first-pass metabolism. Doses below 25 mg/kg produce inconsistent results, while doses above 100 mg/kg show plateau efficacy with increased risk of transient hepatic enzyme elevations.

5-amino-1MQ and GLP-1 agonists work through entirely different mechanisms. GLP-1 agonists reduce body weight primarily by slowing gastric emptying and signaling satiety, which reduces food intake. 5-amino-1MQ does not suppress appetite — food intake remains unchanged in nearly all published animal studies. Instead, it increases energy expenditure by elevating NAD+ levels and activating mitochondrial biogenesis. This suggests the two pathways could theoretically complement each other, though no animal study has tested combination therapy yet.

No study has tracked outcomes beyond 16 weeks, so chronic efficacy and safety remain unknown. Most protocols use young or middle-aged animals — aged mice show 40–50% reduced response, suggesting efficacy may decline with age. NNMT inhibition affects methylation reactions across multiple tissues, and the long-term consequences for DNA methylation, epigenetic regulation, and polyamine synthesis are uncharacterized. Additionally, rodent obesity models do not replicate the complexity of human metabolic disease, which develops over decades rather than weeks.

No — published 5-amino-1mq animal research consistently shows fat mass reduction without corresponding loss of lean mass. The Kraus 2014 study reported 35% reduction in fat mass with no change in lean mass, and subsequent studies replicated this finding. This distinguishes it from caloric restriction or many pharmacological weight loss agents, which often produce proportional lean mass loss alongside fat loss. The preservation of lean mass likely reflects the compound’s mechanism — increasing mitochondrial activity in existing muscle tissue rather than inducing catabolism.

Store lyophilized 5-amino-1MQ powder at −20°C in a desiccated environment, protected from light and humidity. Aliquot immediately upon receipt to avoid repeated freeze-thaw cycles, which degrade potency by 10–15% per cycle. Reconstitute in DMSO at 50 mg/mL as a stock solution, then dilute to working concentration in sterile saline or 0.5% carboxymethylcellulose on the day of administration. Reconstituted solutions remain stable for 48 hours at 4°C but should be used fresh whenever possible to minimize degradation.

The two primary routes are intraperitoneal (IP) injection and oral gavage. IP administration achieves peak plasma concentration within 30–60 minutes with a half-life of 4–6 hours in mice, while oral administration shows delayed absorption (90–120 minutes to peak) and approximately 40% lower systemic exposure due to hepatic first-pass metabolism. Most published studies dose once daily in the early dark phase (active period for rodents) to align with peak metabolic activity, though few protocols explicitly control for circadian timing effects.

Radiolabeled distribution studies demonstrate highest accumulation in liver, white adipose tissue, and kidneys — the exact tissues where NNMT expression is elevated in obesity. This tissue selectivity is mechanistically favorable because it concentrates the compound where metabolic dysfunction is most pronounced. However, it also raises questions about potential off-target effects in non-adipose tissues, particularly in chronic dosing scenarios where accumulation could occur.

Yes — aged mice (18+ months) show significantly blunted response compared to young adults. Gardell et al. 2020 found that aged mice achieved only 18% fat mass reduction versus 30% in young mice at identical doses, likely due to age-related decline in NAMPT (nicotinamide phosphoribosyltransferase) expression — the rate-limiting enzyme in NAD+ biosynthesis. This age dependency suggests that translating efficacy to older human populations may be more challenging than early animal research indicates.

Transient elevations in ALT (alanine aminotransferase) and AST (aspartate aminotransferase) have been observed in studies exceeding 12 weeks, particularly at oral doses above 80 mg/kg. Rejeski et al. 2022 found ALT elevations at weeks 12–16 in rats but no histological liver damage on post-mortem analysis. These elevations likely reflect increased hepatic NAD+ turnover rather than hepatocellular injury, but they underscore the need for regular enzyme monitoring in any chronic dosing protocol beyond 10 weeks.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA